Rodríguez-Pintó Ignasi, Cervera Ricard, Espinosa Gerard
Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.
Servei de Malalties Autoimmunes, Hospital Clínic, Villarroel 170, 08036-Barcelona, Catalonia, Spain.
Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30. doi: 10.1177/1759720X14554793.
The catastrophic antiphospholipid syndrome (CAPS) is characterized by thrombosis in more than three organs or systems developing over a short period of time. Despite conventional treatment with a combination of anticoagulation plus corticosteroids plus plasma exchange, and/or intravenous immunoglobulin, mortality remains high and some patients suffer from recurrent CAPS episodes. In selected patients, new therapies such as rituximab may be a treatment option. In this review, the rationale for using rituximab in CAPS is discussed.
灾难性抗磷脂综合征（CAPS）的特征是在短时间内三个以上器官或系统发生血栓形成。尽管采用抗凝、皮质类固醇和血浆置换及/或静脉注射免疫球蛋白的联合传统治疗，但死亡率仍然很高，一些患者会反复出现CAPS发作。对于特定患者，诸如利妥昔单抗等新疗法可能是一种治疗选择。在本综述中，讨论了在CAPS中使用利妥昔单抗的基本原理。
